文献速递核素与放射性配体治疗放射性药物与辐射防护

177Lu-PSMA放射性配体治疗中肾脏剂量估算:基于减少剂量测定是否可行?

Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
PubMed 文献 · J Nucl Med · 2021-06-04

该研究分析了59例接受至少2周期177Lu-PSMA-617治疗的前列腺癌患者,评估治疗前肾功能能否预测后续肾脏剂量,以及基于第一周期剂量测定预测治疗结束时累积肾脏剂量的可行性。结果显示治疗前肾功能不能可靠预测肾脏剂量,而基于第一周期个体化剂量测定的外推能高度预测累积肾脏剂量,整合每隔一个周期的剂量信息可进一步改善预测。

要点

  • 治疗前肾功能(eGFR、MAG3清除率)不能可靠预测后续肾脏吸收剂量。
  • 基于第一周期个体化剂量测定的累积肾脏剂量预测优于人群平均剂量。
  • 整合第3、5周期剂量信息可进一步提高累积肾脏剂量预测准确性。

核心结论

  • 治疗前肾功能不能预测177Lu-PSMA-617治疗中的后续肾脏剂量。
  • 基于第一周期个体化剂量测定的外推能高度预测治疗结束时累积肾脏剂量。
  • 整合每隔一个周期的剂量信息可进一步改善预测。
  • 由于个体间变异大,建议进行个体化剂量测定。

研究设计与样本

  • 回顾性分析59例接受至少2周期177Lu-PSMA-617治疗的前列腺癌患者。
  • 治疗中位剂量为6 GBq/周期,间隔6-8周,共进行176个周期,中位3周期/患者。
  • 每个周期第0-3天及第6-9天中某一天行SPECT/CT体素基三维剂量测定。
  • 将治疗前肾功能(eGFR、MAG3清除率)与肾脏剂量进行相关性分析。
  • 将治疗结束时累积肾脏剂量与基于人群平均肾脏剂量、个体第一周期肾脏剂量、以及第1、3、5周期每给予活度的平均肾脏剂量的估算值进行比较。

主要发现

  • 全部176个周期的平均肾脏剂量每给予活度为0.67 ± 0.24 Gy/GBq(范围0.21-1.60 Gy/GBq)。
  • MAG3清除率和eGFR不是后续肾脏吸收剂量的可靠预测因子,效应量小(R²=0.080和0.014,P=0.039和0.375)。
  • 所有简化累积肾脏剂量估算均与实测肾脏剂量显著相关(P<0.001)。
  • 基于个体第一周期剂量的估算比基于人群平均肾脏剂量的估算更准确(R²=0.853 vs. 0.560)。
  • 纳入第3和第5周期剂量时估算最佳(R²=0.960)。

关键数值与推荐

  • 平均肾脏剂量每给予活度为0.67 ± 0.24 Gy/GBq(范围0.21-1.60 Gy/GBq),基于176个周期。
  • MAG3清除率与肾脏剂量相关R²=0.080(P=0.039),eGFR相关R²=0.014(P=0.375)。
  • 基于个体第一周期剂量估算累积肾脏剂量R²=0.853,基于人群平均剂量R²=0.560。
  • 纳入第3和第5周期剂量信息时估算R²=0.960。

临床怎么用

  • 不应仅凭治疗前肾功能预测肾脏剂量,应进行个体化剂量测定。
  • 可利用第一周期剂量测定外推累积肾脏剂量,减少后续剂量测定次数。
  • 整合第3、5周期剂量信息可提高累积肾脏剂量预测准确性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The radiation dose to the kidneys should be monitored in prostate cancer patients treated with radioligand therapy (RLT) targeting the prostate-specific membrane antigen (PSMA). We analyzed whether pretherapeutic kidney function is predictive of subsequent kidney dose and to what extent the cumulative kidney dose at the end of multiple therapy cycles can be predicted from a dosimetry based on the first cycle. Methods: Data of 59 patients treated with at least 2 cycles of 177Lu-PSMA-617 (PSMA RLT) were analyzed. Treatment (median, 6 GBq/cycle) was performed at 6- to 8-wk intervals, accompanied by voxel-based 3-dimensional dosimetry (measured kidney dose) with SPECT/CT on each of days 0-3 and once during days 6-9. Pretherapeutic kidney function (estimated glomerular filtration rate, mercaptoacetyltriglycine clearance) was correlated to the kidney doses. Cumulative kidney doses at the end of treatment were compared with a dose estimated from the population-based mean kidney dose, individual first-cycle kidney dose, and mean kidney doses of cycles 1, 3, and 5 per administered activity. Results: In total, 176 PSMA RLT cycles were performed, with a median of 3 cycles per patient. The average kidney dose per administered activity of all 176 cycles was 0.67 ± 0.24 Gy/GBq (range, 0.21-1.60 Gy/GBq). Mercaptoacetyltriglycine clearance and estimated glomerular filtration rate were no reliable predictors of subsequent absorbed kidney dose and showed only small effect sizes (R 2 = 0.080 and 0.014 [P = 0.039 and 0.375], respectively). All simplified estimations of cumulative kidney dose correlated significantly (P < 0.001) with measured kidney doses: estimations based on the individual first-cycle dose were more accurate than the use of the population-based average kidney dose (R 2 = 0.853 vs. 0.560). Dose estimation was best when the doses of cycles 3 and 5 were included as well (R 2 = 0.960). Conclusion: Pretherapeutic renal function was not predictive of subsequent kidney dose during therapy. Extrapolation of individual data from dosimetry of the first cycle was highly predictive of the cumulative kidney dose at the end of treatment. This prediction was further improved by the integration of dose information from every other cycle. In any case, because of a high interindividual variance, an individual dosimetry is advisable.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mix M, Renaud T, Kind F, et al. Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible? J Nucl Med. 2021. PMID: 34088773. doi:10.2967/jnumed.121.262245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。